FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Core Insights - The market value of public funds' holdings in Hong Kong stocks reached 1.33 trillion yuan in Q3 2025, with passive funds surpassing active funds for the first time since 2017 [2][4]. Group 1: Market Trends - The market value of public funds' investments in Hong Kong stocks reached 13,255 billion yuan, with passive funds holding 7,000 billion yuan (52.8%) and active funds holding 6,255 billion yuan (47.2%) [4][5]. - The significant increase in passive fund holdings, which rose by 73% compared to Q2 2025, indicates a growing trend of capital flowing into the Hong Kong market through ETF products [5][6]. Group 2: Fund Performance - The top-performing ETFs in Q3 2025 included the Fuqua Hong Kong Internet ETF, Hua Bao Hong Kong Internet ETF, and Huaxia Hang Seng Technology Index ETF, with substantial increases in fund shares [6][7]. - Active funds showed a preference shift towards sectors like healthcare and materials, while reducing exposure to telecommunications and finance [8]. Group 3: Investment Strategies - Despite market fluctuations, some active fund managers increased their positions in Hong Kong stocks, focusing on technology core assets due to favorable valuations [9]. - The overall trading volume in the Hong Kong market has significantly increased, with average daily turnover reaching 2,579 billion HKD, nearly doubling from the previous year [11].

Group 1 - The core viewpoint emphasizes that Western investors are underestimating China, leading to missed investment opportunities due to fear of risks [1][2] - William Ford, CEO of the investment firm, highlights the rise of ambitious Chinese entrepreneurs who are pursuing global strategies across various sectors, including industrial automation and healthcare technology [1][2] - The recent thawing of US-China relations and the recovery of the Hong Kong stock market present new investment opportunities [2] Group 2 - The Hong Kong capital market has seen a revival, with 42 companies going public in the first half of the year, raising HKD 107.1 billion [2] - The firm has invested approximately USD 8 billion in over 40 companies in China since entering the market in 2000, with Chinese investments accounting for 10% to 15% of its global portfolio [2] - There has been a structural shift in foreign direct investment (FDI) in China, with a significant increase in the number of new foreign-invested enterprises, despite a decline in actual foreign capital used [4] Group 3 - The Chinese pharmaceutical industry is rapidly advancing, becoming the second-largest new drug development country after the US, with a focus on cost-effective and faster drug production [5] - The Chinese biopharmaceutical sector is increasingly licensing innovative drugs to Western pharmaceutical giants, with projections indicating that one-third of licensing deals in 2024 will come from China [4][5] - The competitive edge of Chinese companies is shifting from cost-based advantages to quality and innovation, as exemplified by companies like BYD and Xiaomi [5]

Group 1 - The core viewpoint emphasizes that Western investors are underestimating China, leading to missed investment opportunities, particularly in innovation and entrepreneurship [1][3] - William Ford, CEO of the investment firm, highlights the rise of ambitious Chinese entrepreneurs aiming for global leadership across various sectors, including industrial automation and healthcare technology [1][3] - The recent thawing of US-China relations and the recovery of the Hong Kong stock market present new investment opportunities, with Ford noting a new balance in bilateral relations [3] Group 2 - The Hong Kong capital market has seen a resurgence, with 42 companies going public in the first half of the year, raising HKD 107.1 billion, marking a significant recovery from previous years [3][4] - The number of newly established foreign-invested enterprises in China increased by 16.2% year-on-year from January to September 2023, indicating a structural shift in foreign direct investment [4] - Ford expresses optimism about the potential for successful IPOs in Hong Kong for outstanding Chinese companies, particularly in sectors like industrial automation, consumer electronics, and life sciences [4] Group 3 - China's pharmaceutical industry is rapidly advancing, becoming the second-largest new drug development country globally, with a notable increase in the number of innovative drugs produced at lower costs [5] - The Chinese pharmaceutical innovation sector is transitioning from quantity to quality, gaining international recognition and competitiveness against top global pharmaceutical companies [5] - Ford points out that Chinese companies are now focusing on producing higher quality products while maintaining cost competitiveness, exemplified by companies like BYD and Xiaomi [5]

Group 1 - The Hong Kong stock market saw significant gains on November 10, with the Hang Seng Index rising by 1.55% to close at 26,649.06 points, the Hang Seng Tech Index increasing by 1.34% to 5,915.56 points, and the National Enterprises Index up by 1.90% to 9,443.24 points [1] - The Hang Seng Index opened at 26,319.40 points, fluctuated around this level in the morning, and surged in the afternoon, ultimately gaining 407.23 points with a total turnover exceeding 214.7 billion HKD [1] - The southbound trading under the Stock Connect saw a net inflow of over 6.6 billion HKD on the same day [1] Group 2 - Most sectors experienced upward movement, including biopharmaceuticals, technology, real estate, gold, banking, insurance, brokerage, and new consumption, while sectors like coal, lithium batteries, and building materials showed mixed results, and chips and electricity sectors mostly declined [1] - Notable individual stock performances included Pop Mart rising by 8.11%, China Resources Land increasing by 4.45%, BYD gaining 3.98%, and Ideal Auto up by 2.39%, while SMIC fell by 0.99% [1] - Among the top three stocks by trading volume, Tencent Holdings rose by 2.44% with a turnover exceeding 9.3 billion HKD, Alibaba increased by 2.06% also with over 9.3 billion HKD in turnover, and Xiaomi Group saw a slight increase of 0.28% with a turnover exceeding 6.9 billion HKD [2]

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 3.51 million shares on November 7, 2025, due to the exercise of options [1] Company Summary - The company will issue 3.51 million shares as a result of option exercises [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 3.51 million shares on November 7, 2025, due to the exercise of options [1] Company Summary - The company is set to issue 3.51 million shares as a result of option exercises [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Group 1: Market Trends - The chemical sector experienced a counter-trend rise on November 7, with related ETFs showing significant gains [1][4] - Multiple chemical and new materials ETFs saw increases of over 3% on November 7, while several new energy ETFs rose by more than 2% [4][5] - The Hong Kong biotech sector faced declines, with leading pharmaceutical stocks dropping over 3% [7] Group 2: ETF Performance - Several Hong Kong stock ETFs saw substantial net inflows recently, particularly in the Hang Seng Technology and Hong Kong innovative drug sectors [2][8] - The A500 ETFs showed high trading activity, with four funds exceeding 20 billion yuan in scale, led by Huatai-PB's A500 ETF at 26.463 billion yuan [6][7] - Overall, nearly 20 billion yuan flowed into ETFs, with significant investments in sectors like securities, banking, and electric grid equipment [10] Group 3: Innovation Drug Sector Outlook - The Hong Kong innovative drug index has dropped over 18% since its peak in September, but many institutions believe the sector may soon rebound [3][11] - Fund managers suggest that the current market conditions present a high-probability zone for long-term investments in the biopharmaceutical sector, recommending balanced allocations across various sub-sectors [11][12] - Upcoming international conferences and positive corporate earnings are expected to act as catalysts for the innovative drug sector [12]